Healthequity (HQY) Cost of Revenue (2013 - 2026)

Healthequity has reported Cost of Revenue for 14 years, with the latest figure at $92.8 million in Q3 2026.

• On a quarterly basis, Cost of Revenue changed 0.5% year-over-year to $92.8 million in Q3 2026; TTM through Jul 2026 was $391.6 million, a 8.05% decrease from a year earlier, with the FY2026 full-year figure at $400.3 million, down 5.25% from the prior year.
• Cost of Revenue was $92.8 million for Q3 2026 at Healthequity, down from $98.3 million in the prior quarter.
• The five-year high for Cost of Revenue was $122.8 million in Q1 2025, with the low at $87.9 million in Q3 2022.
• Average Cost of Revenue over 5 years is $97.8 million, with a median of $96.0 million recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue grew 23.93% in 2025, then dropped 13.3% in 2026.
• Over 5 years, Cost of Revenue stood at $88.8 million in 2022, then increased by 1.43% to $90.0 million in 2023, then rose by 14.85% to $103.4 million in 2024, then decreased by 9.0% to $94.1 million in 2025, then fell by 1.41% to $92.8 million in 2026.
• The last three Cost of Revenue figures came in at $92.8 million (Q3 2026), $98.3 million (Q2 2026), and $106.4 million (Q1 2026), per Business Quant data.